search Created with Sketch.
search Created with Sketch.

Advertisement

dermwire-tv-logo Created with Sketch.
dermwire-tv-logo Created with Sketch.

DermWireTV: Climate Change and Skin, Wynzora, Tremfya, Rinvoq Updates

July 30, 2020

The vast majority of dermatologists around the world—95.6 percent—believe climate change is occurring, and 88 percent think it will impact the incidence of skin diseases, according to the first international survey of dermatologists on the topic, conducted online by the International Society of Dermatology's Climate Change Committee. FDA has approved MC2 Therapeutics Wynzora Cream for once-daily topical treatment of plaque psoriasis in adults. Tremfya is the first IL-23 inhibitor FDA-approved for active psoriatic arthritis. AbbVie's upadacitinib met both primary and all secondary endpoints in Measure Up 2, the second Phase 3 study in individuals with moderate to severe atopic dermatitis.

Advertisement

In This Series

View More

Advertisement